6:32 PM
 | 
Jul 30, 2014
 |  BC Extra  |  Company News

BioMarin sells Priority Review voucher

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said it sold a Priority Review voucher to Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) for $67.5 million late Wednesday and separately reported 2Q14 financial results. BioMarin gained the voucher earlier this year following FDA's approval of the company's Vimizim elosulfase...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >